UNSPSC 51334410: Lusaperidone

This classification denotes an antipsychotic agent with the molecular formula C22H21N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5KTD2O86CB, chemically known as 3-(2-(3,4-dihydrobenzofuro(3,2-c)pyridin-2(1h)-yl)ethyl)-2-methyl-4h-pyrido(1,2-a)pyrimidin-4-one. but generally known as lusaperidone, which bears US NIH Compound Identifier 3045401. The term LUSAPERIDONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 14, No. 3, 2000, List 44).

Most nations schedule lusaperidone under HS 29349990 and SITC 51579. As of Q4 2014, LUSAPERIDONE remains the US FDA Preferred Term for this commodity. Lusaperidone bears US NLM identifiers UMLS ID C2983866 and NCI Concept Code C90760. SMILES: CC1=C(C(=O)N2C=CC=CC2=N1)CCN3CCC4=C(C3)C5=CC=CC=C5O4.

UNSPSC 51334410 Lusaperidone, a Commodity code, shows minimal recent state and local procurement activity focused on this specific pharmaceutical. The recent opportunity under this code involves Seminole County, Florida's procurement of naloxone and safe drug deactivation systems, though this represents a tangential match to the code's nominal scope rather than a direct lusaperidone procurement. State and local governments use this Commodity code to acquire pharmaceutical products for public health and community safety initiatives, but the actual buying patterns remain unclear due to limited recent solicitation volume under the code itself.

Seminole County, Florida has posted the primary visible recent opportunity: IFB 60459723LAS, an invitation for bid issued June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually, with quarterly deliveries to the Seminole County Community Health Building at 520 W. Lake Mary Blvd, Sanford, FL 32771 and a response deadline of July 26, 2026 at 2:00 pm. The contract carries an initial two-year term with a one-year renewal option, fixed-fee pricing, and may be funded through FEMA. Bidders must provide unit costs for each line item, comply with drug-free workplace certification and E-Verify requirements, and maintain workers' compensation, commercial general liability, and professional liability insurance. No explicit set-aside designations for disadvantaged enterprises are noted in the procurement. The mismatch between the code name (lusaperidone) and the actual solicitation (naloxone procurement) suggests either a classification error in the source or minimal current activity under this specific Commodity code in state and local markets.